The investigators reported the results of a prospective, randomized, phase 3 trial studying the best individual therapy for women who have node-negative, estrogen-receptor‒positive (ER-positive) ...
Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...
The Oncotype DX Breast Recurrence Score® test, which has been used by over 1.5 million patients, indicates the likelihood of your cancer recurring based on the biology of your tumor. 1,2,3,4 It is ...
A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast Recurrence Score ® result provides more accurate estimates about that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback